Divis Labs hits 52-week low

In past six months, the stock slipped 52% as compared to 4% rise in the S&P BSE Sensex.

Divi’s Laboratories hit 52-week low of Rs 607, down 4% on BSE in early morning trade after the company on Saturday said that the US drug regulator has issued a warning letter for its unit-II at Visakhapatnam, Andhra Pradesh.

“The US Food and Drug Administration (USFDA) have issued a Warning Letter for the company's Unit-II at Visakhapatnam,” Divis Laboratories said in a BSE filing.

The company responded to the US-FDA inspection observations with an appropriate remediation process to overcome the deficiencies observed, it added.

The company said, in the import alert issued, US-FDA has exempted several products